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Abstract: A third of adults with AIDS and cryptococcal meningitis (CM) develop immune
reconstitution inflammatory syndrome (IRIS) after initiating antiretroviral therapy (ART), which is
thought to result from exaggerated inflammatory antigen-specific T cell responses. The contribution of
monocytes to the immunopathogenesis of cryptococcal IRIS remains unclear. We compared monocyte
subset frequencies and immune responses in HIV-infected Ugandans at time of CM diagnosis
(IRIS-Baseline) for those who later developed CM-IRIS, controls who did not develop CM-IRIS
(Control-Baseline) at CM-IRIS (IRIS-Event), and for controls at a time point matched for ART duration
(Control-Event) to understand the association of monocyte distribution and immune responses with
cryptococcal IRIS. At baseline, stimulation with IFN-γ ex vivo induced a higher frequency of TNF-α-
and IL-6-producing monocytes among those who later developed IRIS. Among participants who
developed IRIS, ex vivo IFN-γ stimulation induced higher frequencies of activated monocytes, IL-6+,
TNF-α+ classical, and IL-6+ intermediate monocytes compared with controls. In conclusion, we have
demonstrated that monocyte subset phenotype and cytokine responses prior to ART are associated
with and may be predictive of CM-IRIS. Larger studies to further delineate innate immunological
responses and the efficacy of immunomodulatory therapies during cryptococcal IRIS are warranted.
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1. Introduction
Cryptococcus neoformans is the most common cause of HIV-associated adult meningitis in
sub-Saharan Africa, accounting for 15–20% of AIDS-related mortality [1,2]. The primary immune
response to Cryptococcus involves fungal recognition by innate immune cells and subsequent expansion
of Cryptococcus-specific CD4+ T cells to control the infection [3]. In immunocompromised persons,
this immune sequence is impaired, resulting in ineffective fungal clearance.
Up to 30% of patients with cryptococcal meningitis (CM) develop paradoxical immune
reconstitution inflammatory syndrome (IRIS), which is a clinical deterioration after initiating
antiretroviral therapy (ART) [4,5]. IRIS is proposed as an aberrant inflammatory response to persistent
cryptococcal antigens during recovery of the host immune system [6]. These CM-IRIS events may
manifest as relapsing aseptic meningitis, increased intracranial pressure, new focal neurologic signs,
intracranial cryptococcomas, lymphadenopathy, and/or abscess formation [7–9].
CM-IRIS risk factors include higher fungal burden or cryptococcal antigen titer at CM
diagnosis [9–11], positive cerebrospinal fluid (CSF) fungal culture when starting fluconazole
400 mg/day consolidation [12], and paucity of initial CSF immune response as suggested by low levels
of: CSF white cells, interferon-γ (IFN-γ), tumor necrosis factor (TNF)-α, interleukin (IL)-2, IL-6, IL-8,
and IL-17 [12–14].
The pathologic role of T cells in IRIS may derive from dysregulated expansion of activated
antigen-specific T cells [15–17] resulting in inflammatory cytokine responses. However, neither the
antigen-specificity of the T cell response during IRIS nor the role of innate myeloid cells in CM-IRIS
has been well defined. The accumulation of primed antigen presenting cells is proposed to create a
state of immunologic hyper-responsiveness to T-cell signaling upon immune recovery [9–18]. Thus,
when T-cells are restored following ART initiation, antigen-specific CD4+ T-cells then provide a burst
of IFN-γ with subsequent activation of the primed macrophages, which release proinflammatory
cytokines, such as IL-6 and TNF-α. Innate cytokine signaling may precede IRIS-associated
immunopathology [9].
In this study, we evaluated the role and function of peripheral blood monocytes from ART-treated
HIV-infected participants treated for CM, and who did or did not subsequently develop CM-IRIS.
By characterizing their phenotype and cytokine responses before and upon ex vivo stimulation with
IFN-γ, a proxy for CD4+ T cell driven activation, we evaluated monocyte activation and functional
patterns associated with CM-IRIS.
2. Materials and Methods
2.1. Study Participants
We enrolled ART-naïve participants in a sub-study of the Cryptococcal Optimal ART Timing
(COAT) Trial [19], a randomized trial testing the timing of early (1–2 weeks) versus deferred (4–6 weeks)
ART initiation after cryptococcal meningitis. Participants received amphotericin-based (1 mg/kg)
combination antifungal therapy with fluconazole (800 mg/day). ART consisted of zidovudine,
lamivudine, and efavirenz. Peripheral blood mononuclear cells (PBMCs) were prospectively collected
at serial longitudinal time points and at time of suspected possible IRIS event. A diagnosis of
CM-IRIS was made per the consensus CM-IRIS case definition [20], with external adjudication by a
three-physician panel and graded as definite, probable, or possible IRIS based on the available clinical
and CSF information. Institutional review board approvals were obtained from the School of Medicine
Ethics review committee at Makerere University (REF 2009-022, 29 January 2009) and the University of
Minnesota (0810M49622, 11 February 2009), and written informed consent were obtained.
2.2. Peripheral Blood Mononuclear Cells (PBMCs) Stimulation
PBMCs were isolated by density centrifugation gradient (Ficoll 1077, Sigma-Aldrich, St. Louis,
MO, USA) and cryopreserved in RPMI-1640 with fetal bovine serum (20%), dimethyl sulphoxide
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(10%), and penicillin/streptomycin (1%), in liquid nitrogen. PBMCs (3–5) × 106) were thawed in
complete media (RPMI-1640 with 10% FBS, 2% HEPES, 2% L-Glutamine, 1% Pen/Strep) and incubated
in triplicate wells with phosphate buffered saline (PBS; 100 µL/well) (Sigma-Aldrich, St. Louis, MO,
USA) as negative control, lipopolysaccharide (LPS; 10 ng/mL) (Invivogen, San Diego, CA, USA) as
positive control, or recombinant interferon-γ (IFN-γ; 150 U/mL) (Genentech, Inc., San Francisco,
CA, USA).
2.3. Surface Flow Cytometric Staining
Cell phenotype, activation state, and percentage of monocyte subsets were determined
by 8-color flow cytometry using a FACSCanto II (BD Biosciences, San Jose, CA, USA).
Differential gating was based on size and granularity (Figure 1a,b), with monocyte lineage defined
as CD4+loD11c+CD14+CD16+/−, classical monocytes as CD14hi++CD16−, intermediate monocytes as
CD14++CD16+, and non-classical monocytes as CD14+loCD16++ (Figure 1d) [21,22].
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Figure 1. Flow cytometry gating strategy for monocytes. Analytic gating of flow cytometry data: (a) 
monocytes were identified from singlet cells; (b) monocytes were selected based on forward and side 
scatter; (c) cells expressing low levels of CD4 were selected; (d) cells co-expressing CD4loCD11c were 
then identified; (e) gating on monocyte subsets was performed with classical monocytes as 
(CD14hi++CD16−), intermediate monocytes as (CD14++CD16+), and non-classical monocytes as 
(CD14+CD16++); (f) classical monocyte activation shown by co-expression of programmed death 
ligand-1 (PD-L1) and CD25 is shown; (g) gating on the fluorescence minus one (FMO) controls is used 
to set gates for CD25 and PD-L1; (h) expression of interleukin (IL)-6 by classical monocytes following 
interferon (IFN)-γ stimulation for a representative patient; (i) expression of tumor necrosis factor 
(TNF)-α by classical monocytes following IFN-γ stimulation for a representative patient. 
Figure 1. Flow cytometry gating strategy for monocytes. Analytic gating of flow cytometry data:
(a) monocytes were identified from singlet cells; (b) monocytes were selected based on forward and
side scatter; (c) cells expressing low levels of CD4 were selected; (d) cells co-expressing CD4loCD11c
were then identified; (e) gating on monocyte subsets was performed with classical monocytes as
(CD14hi++CD16−), intermediate monocytes as (CD14++CD16+), and non-classical monocytes as
(CD14+CD16++); (f) classical monocyte activation shown by co-expression of programmed death
ligand-1 (PD-L1) and CD25 is shown; (g) gating on the fluorescence minus one (FMO) controls is used
to set gates for CD25 and PD-L1; (h) expression of interleukin (IL)-6 by classical monocytes following
interferon (IFN)-γ stimulation for a representative patient; (i) expression of tumor necrosis factor
(TNF)-α by classical monocytes following IFN-γ stimulation for a representative patient.
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Cells were stained with monoclonal antibodies reactive with CD14V500 (clone M5E2),
CD274/PD-L1PE (clone MIH1), CD25PE−Cy7 (M-A251), CD16 APC−Cy7 (clone 3G8), CD4V450 (clone
RPA-T4) (BD Biosciences), and CD11cPerCPCy5.5 (clone 3.9, BioLegend, San Diego, CA, USA).
Fluorescence minus one (FMO) controls were used to set gates for CD25 and programmed death-ligand
1 (PD-L1). Unstimulated samples were used to set gates for intracellular cytokines.
2.4. Intracellular Cytokine Staining
Monocyte cytokine responses were determined by intracellular cytokine staining. Following 2 h
of stimulation at 37 ◦C, Brefeldin A (100 µL/mL) (BD) was added and cells were incubated for another
4 h, then overnight at 4 ◦C, and then washed, fixed, and permeabilized with successive washes in
Fluorescence Activated Cell Sorter (FACS) permeabilizing solution (BD Biosciences). The cells were
stained with surface antibodies to define phenotype as above and intracellularly with monoclonal
antibodies reactive with IL-6FITC (clone AS12, BD Horizon) and TNF-αAPC (clone MAb11, BioLegend).
One million events were collected on a FACSCanto II and analyzed using FlowJo version 10.0.5
(TreeStar, Ashland, OR, USA).
2.5. Statistical Analysis
Data were analyzed using GraphPad Prism, version 6.0b (GraphPad Software Inc., La Jolla, CA,
USA) and Spice, version 5.35 (NIAID, Bethesda, MD, USA). Paired samples at diagnosis and CM-IRIS
were compared using the Wilcoxon signed-rank test. Cell phenotype and activation variables were
compared between CM-IRIS and controls using the Mann-Whitney rank sum test. Significance was
defined as p-value ≤ 0.05. Cytokine expression profiles were compared by permutation analysis,
using a 10,000-iteration Monte Carlo simulation model, as described elsewhere [23].
3. Results
We enrolled 17 HIV-infected adults with CM, 11 of whom developed CM-IRIS and 6 of whom did
not develop IRIS at Mulago Hospital in Kampala, Uganda between November 2010 and April 2012.
Blood samples were obtained at CM-diagnosis (n = 15), IRIS-Baseline for participants who went on to
develop CM-IRIS and Control-Baseline for controls who did not develop IRIS; at CM-IRIS (n = 11),
(IRIS-Event), and controls without CM-IRIS at comparable ART duration (n = 6), (Control-Event).
Age, baseline CD4+ and CD8+ T cell counts, cryptococcal antigen (CrAg) titer, plasma HIV
RNA (viral load), cerebrospinal fluid (CSF) protein, and white blood cells were similar among
participants who later developed CM-IRIS and control participants (Table 1). At meningitis diagnosis,
participants who later developed CM-IRIS showed a trend to higher median cryptococcal colony
counts in CSF compared with those who did not develop IRIS (5.33 vs. 3.97 log10 colony forming
units/mL (p = 0.078). Among the entire clinical cohort (n = 172), the median quantitative CSF culture
was 5.1 log10 colony forming units/mL [19].
Among IRIS cases, the median duration from ART initiation to IRIS was 78 days (IQR, 43–144 days).
The six control participants’ samples were obtained at diagnosis (Control-baseline) and at matched
time points of ART duration (Control-event) with CM-IRIS subjects (±14 days), a median of 71 days
(IQR, 63–84 days) after ART initiation.
At CM-IRIS (IRIS-event), the median serum CrAg titer had decreased three-fold from CM
diagnosis (p = 0.078) (IRIS-baseline) (Table 1). Among controls, serum CrAg titer did not change
significantly 81,920 (Interquartile range (IQR), 5,122–245,760) at CM diagnosis to 46,080 (IQR, 3–163,840;
p = 0.681) at the later time point. CD4+ T cell numbers at baseline were low, particularly among those
who developed IRIS (Table 1). By three months following initiation of ART, the proportion of CD4+
and CD8+ T cells increased in both populations (Table 1). However, at the time of CM-IRIS, the percent
CD4+ T cells was lower among patients experiencing CM-IRIS (p = 0.039), respectively (Figure S1).
In addition to smaller numbers of CD4+ T cells, we also considered that antigen presenting cell
numbers and/or function might be contributing to CM-IRIS.
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Table 1. Characteristics of Participants Who Developed Cryptococcal Meningitis (CM)-immune
reconstitution inflammatory syndrome (IRIS) vs. Participants without CM-IRIS.
Variable Controls (n = 6) CM-IRIS (n = 11) p-Value
Male % 17% 73% 0.05
Age years 35 (±9) 35 (±8) 0.937
Baseline CD4 T cells/µL 8 (5, 166) 6.5 (4, 28) 0.828
CD4 T cells/µL > 3 months after ART 156 (55, 309) 68 (33, 79) 0.256
Baseline CD8 T cells/µL 163 (97, 784) 256 (140, 591) 0.515
CD8 T cells/µL > 3 months after ART 1005 (615, 1086) 831 (565, 997) 0.463
Baseline plasma HIV-1 RNA
(log10copies/mL) 4.93 (±0.34) 5.24 (±0.5) 0.280
Baseline Cryptococcus log10 colony
forming units/mL 3.97 (2.45, 5.26) 5.33 (4.96, 5.46) 0.078
Baseline CSF CrAg titer 4512 (528, 12,192) 7,200 (4048, 16,384) 0.455
Serum CrAg titer at CM-IRIS 40,960 (8960, 102,400) -
CSF CrAg titer at CM-IRIS 12,000 (4672, 16,384) -
CSF protein (mg/dL) 60 (47, 68) 53 (20, 70) 0.471
Baseline CSF white cells/mL 19.5 (<5, 45) <5 (<5, <5) 0.169
Duration from ART initiation (days) 67 (48, 92) 78 (43, 202) 0.737
All values listed as median (IQR) or mean (± SD). Abbreviations: CrAg—Cryptococcal Antigen; CSF—Cerebrospinal
Fluid; ART—Antiretroviral Therapy; HIV—Human Immunodeficiency Virus. Comparison was done using a t-test.
3.1. Baseline Monocyte Subsets
To evaluate a role for monocytic cells in the evolution of CM-IRIS, we measured the numbers
of total monocytes and of the three phenotypic categories of monocyte subsets. Classical monocytes
were the predominant subset at IRIS-Baseline and Control-Baseline (Figure 1d, Figure 2 panel A).
Whereas no differences were detected in the intermediate subset, the frequencies of non-classical
monocytes, the minority subset, were significantly lower at IRIS-Baseline vs. Control-Baseline (0% vs.
4.1%, p < 0.001) (Figure 2 panel A). The frequency of activated non-classical monocytes, as determined
by co-expression of PD-L1 and CD25 (Figure 1e), was significantly lower in CM-IRIS compared with
controls, 0% vs. 11% (6–16%), p < 0.001 (Figure 2 panel B).
In contrast to baseline values, at the time of CM-IRIS, monocyte activation was significantly
elevated in the total monocyte population from those with CM-IRIS compared with cells from
time-matched controls, median frequency, (62% (IQR, 44–76%) vs. 12% (IQR, 5–25%); p < 0.001)
(Figure 2 panel C), but these differences were not confined to one subset. These differences persisted
from baseline to IRIS, and did not change significantly in either group. These data suggest that
activation of monocytes both precedes and accompanies the development of CM-IRIS and may play a
role in the immunopathogenesis of this clinical syndrome.
3.2. Cytokine Expression and Responses at Baseline
To characterize functional differences between monocyte populations isolated during IRIS-event
and Control-event, we examined constitutive and induced expression of two relevant cytokines,
TNF-α and IL-6. At IRIS-baseline, unstimulated monocytes consistently expressed a substantial and
higher median frequency of TNF-α (16% (IQR, 2–31%) than Control-baseline, 0.8% (IQR, 0.3–4%);
p = 0.039) (Figure 3 panel A). Results with IL-6 expression showed no differences. The TLR4 agonist,
LPS, elicited a significant and comparable increase in expression of both cytokines in both groups
(Figure 3 panel A), and significantly increased IL-6 expression compared to unstimulated monocytes
among controls (Figure S2), highlighting the differences in cellular responses between the two groups.
In contrast, stimulation with IFN-γ elicited increased expression of TNF-α and IL-6 by monocytes only
at IRIS-Baseline. Indeed, following IFN-γ stimulation, the median frequency of activated monocytes
expressing TNF-α or IL-6 was higher at IRIS-Baseline compared with Control-Baseline (Table 2).
We found IFN-γ- induced IL-6 and TNF-α expression by activated (PD-L1+CD25+) monocytes was
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higher at IRIS-Baseline compared with Control-Baseline. Thus, spontaneous expression of TNF-α
and, to a lesser extent, IL-6 were increased at IRIS-Baseline, as was the response of both cytokines to
IFN-γ stimulation.
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Figure 2. Monocyte Subsets and Activated (PD-L1+CD25+) Monocyte Subsets. (Panel A) displays
total monocytes and monocyte subsets at CM diagnosis among participants who developed CM-IRIS
(IRIS-baseline) vs. controls without IRIS (Control-baseline); (Panel B) displays activated monocytes
and subsets at time of cryptococcal diagnosis from participants who subsequently developed CM-IRIS
(IRIS-baseline) or matched controls on ART (Control-baseline); (Panel C) displays activated monocytes
and subsets at IRIS-baseline and Control-baseline. Activation was measured by surface co-expression of
programmed death ligand-1 (PD-L1) and CD25 (Interleukin 2 receptor α chain). Bars represent medians;
* represents p < 0.001. Median values were compared using the Mann-Whitney test. Non-classical
monocytes were absent at IRIS-baseline. Data is presented as percentage of monocytes but not
percentage of total white blood cells, as the laboratory did not perform complete blood counts with
every peripheral blood mononuclear cell (PBMC) isolation.
We determined the differential expression of these cytokines in the three monocyte subsets,
including activated populations. Without stimulation, the frequency of TNF-α+ classical monocytes
was higher at IRIS-Baseline compared with Control-Baseline (19% (IQR, 12–37%) vs. 5% (IQR, 3–8%);
p = 0.039), whereas IL-6 expression did not differ (Fig re 3 panel B). IL-6 expression by activat d
non-classical monocytes did not differ between the two group , whereas TNF-α expression by the
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activated non-classical monocytes was lower at IRIS-Baseline compared with Control-Baseline, 0% vs.
6% (2–10%), p = 0.004 (Figure 3 panel C).
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Figure 3. Cytokine Expression by monocytes at Cryptococcal Diagnosis. Frequencies of monocytes
expressing intracellular TNF-α and IL-6 by flow cytometry at IRIS-Baseline and Control-Baseline.
The frequencies of total monocytes expressing TNF-α or IL-6 (Panel A); classical monocytes expressing
TNF-α or IL-6 (Panel B); and activated non-classical monocytes expressing TNF-α or IL-6 (Panel C)
are shown. Cells were stimulated for 6 h with phosphate buffered saline (PBS), lipopolysaccharide
(LPS; positive control), or the Th1 cytokine interferon-γ (IFN-γ; 150 U/mL). Horizontal bars represent
the median value. Median values were compared using the Mann-Whitney test.
Differential responses to IFN-γ among selective subsets were minimal. IFN-γ- inducible
TNF-α+ and IL-6+ non-classical monocytes were less frequent at IRIS-Baseline (Table 2). Similarly,
the proportion of IFN-γ activated (PD-L1+CD25+) TNF-α+ non-classical monocytes was nondetectable
at IRIS-Baseline, compared to Control-Baseline, 0% vs. 3% (IQR, 0–7%) (p = 0.022).
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Table 2. Cytokine expression in circulating monocytes after stimulation with interferon-γ at
control-baseline and IRIS-Baseline.
Monocyte Population with Intracellular
Cytokine Production
Control-Baseline
(n = 5)
IRIS-Baseline
(n = 10) p-Value
All Monocytes
TNF-α+ 7 (3, 16) 33 (6, 52) 0.096
IL-6+ 2.0 (0.8, 7.7) 2.0 (0.6, 22) 0.893
TNF-α+ or IL-6+ 8 (3, 18) 35 (6, 53) 0.050
Activated Monocytes (PD-L1+CD25+)
TNF-α+ 11 (4, 21) 50 (23, 55) 0.026
IL-6+ 3 (1, 13) 27 (6, 28) 0.018
Activated Classical Monocytes (PD-L1+CD25+)
TNF-α+ 13 (7, 26) 42 (19, 56) 0.073
IL-6+ 3 (1, 13) 14 (1, 29) 0.196
Intermediate Monocytes
TNF-α+ 9 (5, 31) 29 (9, 52) 0.291
IL-6+ 5 (2, 36) 13 (1, 33) 0.834
Activated Intermediate Monocytes (PD-L1+CD25+)
TNF-α+ 9 (6, 28) 36 (8, 69) 0.240
IL-6+ 5 (1, 41) 18 (2, 44) 0.743
Activated Non-Classical monocytes (PD-L1+CD25+)
TNF-α+ 3.0 (0, 7) 0.0 0.022
IL-6+ 0.0 (0, 2) 0.0 0.333
All values listed as median % (IQR) unless otherwise noted. p-value determined from Mann-Whitney U test.
Abbreviations: TNF—tumor necrosis factor; IL—Interleukin. Classical monocytes defined as (CD14hi++CD16−),
intermediate monocytes as (CD14++CD16+), and non-classical monocytes as (CD14+loCD16++). One control subject
did not have PBMCs collected at CM diagnosis.
3.3. Cytokine Responses at CM-IRIS
We next compared monocyte responses to IFN-γ in paired samples from the same participants
at IRIS-Baseline and at IRIS-Event. The most prominent differences at IRIS-Event vs. IRIS-Baseline,
respectively, were significantly increased frequencies of IL-6+ cells among total monocytes (23% (7–38%)
vs. 1% (0.7–23%); p = 0.009), among classical monocytes, (24% (7–33%) vs. 11% (1–23%); p = 0.019)
and among activated (CD25+PD-L1+) classical monocytes, (24% (9–39%) vs. 14% (1–29%), p = 0.027)
(Figure 4) (data not shown). Thus, upregulation of IL-6 production was the most consistent intracellular
cytokine marker of CM-IRIS.
Consistent with these paired results over time, the frequencies of IFN-γ-induced IL-6+ monocytes
at IRIS-Event were also higher compared with Control-Event (Table 3). These differences extended
to all monocyte subsets (Table 3, Figure S3). About a quarter to a third of each monocyte subset
from IRIS-Event expressed IL-6 as well as TNF-α. Even in the absence of IFN-γ stimulation,
the frequencies of TNF-α+ and IL-6+ monocytes were significantly elevated among IRIS-Event
compared to Control-Event (Figure S3), further illustrating that monocyte activation and inflammatory
mediators are linked to emergence of CM-IRIS. During IRIS-Event, constitutive and/or IFN-γ-induced
cytokine responses were greater at IRIS-Event compared with Control-Event. A clear demonstration of
IL-6 expression following different experimental conditions is shown in Figure S4.
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Figure 4. Comparison of IL-6 expression by monocyte populations at IRIS-Baseline vs.
IRIS-Event among patients with paired samples. IL-6 intracellular expression was measured in
total monocyt s (Panel A); classical monocytes (Panel B), and a tivated (PDL1+CD25+) classical
monocytes (Panel C) at IRIS-Baseline and IRIS-Event in 10 participants with paired samples. p values
were determined by Wilcoxon rank sum test. At IRIS-Event, monocyte IL-6 expression was elevated
compared to IRIS-Baseline from both unstimulated and IFN-γ-stimulated monocytes.
Table 3. Cytokine Expression in Circulating Monocytes after Stimulation with Interferon-γ at
IRIS-Event or Control-Event.
Monocyte Popu ati wi h Intracellular
Cytokine Production
Control-Event
(n = 6)
IRIS-Event
(n = 11) p-Value
All Monocytes
TNF-α+ 8 (2, 10) 22 (7, 52) 0.091
IL-6+ 0.6 (0.4, 1.3) 25 (8, 37) <0.001
TNF-α+ and IL-6+ 8 (3, 10) 39 (20, 61) 0. 03
Activated Monocytes (PD-L1+CD25+)
TNF-α+ 10 (6, 18) 36 (24, 64) 0.007
IL-6+ 0.4 (0.2, 1.0) 36 (7, 44) <0.001
Classical Monocytes
TNF-α+ 9 (3, 14) 29 (23, 47) 0.005
IL-6+ 1.5 (0.4, 2.0) 24 (8, 30) <0.001
Activated Classical Monocytes
TNF-α+ 7 (1, 17) 26 (17, 45) 0.010
IL-6+ 0.6 (0.4, 1.3) 21 (9, 36) <0.001
Intermediate Monocytes
TNF-α+ 7 (4, 11) 25 (16, 76) 0.020
IL-6+ 0.9 (0.4, 1.5) 23 (7, 40) <0.001
Activated Intermediate Monocytes
TNF-α+ 6 (5, 13) 24 (13, 72) 0.025
IL-6+ 0.5 (0.1, 0.7) 25 (8, 46) 0.003
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Table 3. Cont.
Monocyte Population with Intracellular
Cytokine Production
Control-Event
(n = 6)
IRIS-Event
(n = 11) p-Value
Non-Classical Monocytes
TNF-α+ 0 0 (0, 39) 0.102
L-6+ 0 0 (0, 16) 0.102
Activated Non-Classical Monocytes
TNF-α+ 0 0 (0, 80) 0.353
IL-6+ 0 0 0.515
Control-Event (n = 6) participants were matched for ART duration to the 11 participants at IRIS-Event.
All values listed as median % (IQR) unless otherwise noted. p-value determined from Mann-Whitney U test.
Abbreviations: TNF—tumor necrosis factor; IL—Interleukin. Classical monocytes defined as (CD14hi++CD16−),
intermediate monocytes as (CD14++CD16+), and non-classical monocytes as (CD14+loCD16++).
We assessed the monocyte functional phenotype following IFN-γ stimulation at IRIS-Event
compared with Control-Event by measuring the possible combinations of 1- or 2-cytokine responses.
At IRIS-Event, the immune responses were characterized by significantly elevated dual-function
monocytes producing IL-6- and TNF-α, with a frequency of 39% (IQR, 20–61%) compared to 8% (IQR,
3–10%) at Control-Event, p = 0.045 (Figure 5).J. Fungi 2017, 3, 28 11 of 17 
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Figure 5. Functional Monocyte Cytokine responses to IFN-γ Stimulation. Peripheral blood
mononuclear cells collected at IRIS-Event and Control-Eve t wer stimulat d with interferon-γ (IFN-γ).
The bar chart shows each of the three possible combination responses on the x-axis. The percentage of
the total cytokine response is hown on the y- xis, w th the fill d bar representing the interquartile
range and a black line at the median. Responses at Control-Event are shown as blue bars, responses at
IRIS-Event are shown as red bars on the graph. Statistically significant differences (p < 0.05) by
rank-sum testing are indicated by the plus sign. The pie charts show the representative fractions
according to the pie-slice colors shown at the bottom of the bar chart, with color-coded slices indicating
the contributions of IL-6 and TNF-α (red), only IL-6 (green), and only TNF-α (blue) to the 2- and
1-function responses. Statistical comparisons of the overall responses by permutation testing are shown
in the pie category test result chart where the red arc represents IL-6 expression and the green arc
represents TNF-a producing cells. Patients with CM-IRIS had immu e responses characterized by
significantly elevated dual-function monocytes producing IL-6- and TNF-α compared to controls.
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In summary, significantly different monocyte subset distribution, particularly non-classical
monocytes, and function were detected at IRIS-Event and IRIS-Baseline compared to Control-Event
and Control-Baseline. These differences extended to the distribution of monocyte subsets, particularly
non-classical monocytes at baseline, to the degree of monocyte activation (CD25+PD-L1+) at
IRIS-Event, and, in particular, to the expression of intracellular proinflammatory cytokines (IL-6
and, less consistently, TNF-α) prior to ART and subsequently at IRIS-Event with and without
IFN-γ stimulation.
4. Discussion
There is a notable paucity of data on innate immune responses occurring during cryptococcal
IRIS, and, in particular, the role of monocytes [24,25]. We have shown that monocyte phenotype and
function may predict the incidence of cryptococcal IRIS, with the absence of non-classical monocytes
at CM diagnosis and upregulation of IFN-γ induced IL-6 expression that precedes and accompanies
the development of CM-IRIS.
Monocytes circulate in peripheral blood and migrate into tissues, maturing into phenotypically
and functionally distinct macrophages at different anatomical locations. The main functions
of monocytes include phagocytosis, antigen presentation, and cytokine production. The three
subsets of circulating monocytes are characterized by the differential expression of surface
CD14 and CD16: classical (CD14hi++CD16−), intermediate (CD14++CD16+), and non-classical
monocytes (CD14lo+CD16++), each with certain unique phenotypic and functional parameters [21].
Classical monocytes can develop into intermediate monocytes and then to non-classical CD14+CD16++
monocytes, also described as patrolling monocytes [21]. The absence of non-classical monocytes prior
to ART in patients with cryptococcal meningitis was associated with the incidence of IRIS, similar to
paradoxical tuberculosis (TB)-IRIS, where the non-classical monocyte subset was also significantly
decreased prior to ART initiation [26]. Non-classical monocytes have been demonstrated in CSF
during the immune response to primary cryptococcal meningitis [25], however, it is unclear whether
the absence of this monocyte subset was associated with poor cryptococcal antigen clearance with
resulting CM-IRIS, as demonstrated in TB-IRIS [26].
During TB-IRIS, dysregulation of monocyte gene expression is functionally related to infection,
inflammation, and inappropriate control of complement activation prior to initiating ART, during ART,
and during the IRIS event [27,28]. Whether this scenario with an intracellular bacterial infection
also occurs during the development of IRIS with an encapsulated fungal pathogen, such as
Cryptococcus, is unknown. Barber and colleagues hypothesize that when patients with low CD4+
T cells acquire an opportunistic infection, subsequent paradoxical IRIS results from accumulated
monocytes/macrophages harboring abundant organisms producing cytokines for cell signaling (e.g.,
IL-6), and then undergoing en masse activation upon an effective T cell response to produce excessive
innate inflammatory cytokines. This activation coincides with the reconstitution of antigen-specific
CD4+ T cells, which deliver previously diminished IFN-γ signaling as ART is initiated [18]. In this study,
we provided a surrogate for restored T-cell signals to the monocyte population by in vitro stimulation
of PBMCs with IFN-γ. By measuring the intracellular expression of the proinflammatory cytokines IL-6
and TNF-α in monocytes from patients with and without CM-IRIS, we simultaneously characterized
measurement and phenotype of cytokine-producing monocytes at the single cell level [29].
We found elevated expression of TNF-α and IL-6 by monocytes at baseline among participants
with future CM-IRIS, suggesting that elevation of these innate cytokines may predict future CM-IRIS,
as demonstrated for IL-6 in TB or herpes virus-associated IRIS [30–34]. IL-6 induced during microbial
infection influences macrophage differentiation and shifts the T helper 1(Th1)/Th2 balance toward
the Th2 axis by promoting IL-4 production and Th2 differentiation to inhibit IFN-γ production
and inhibition of regulatory T cells [9,35]. Another important pathway in the immune response
against fungal infections is Th17, which is associated with increased IFN-γ production by T cells and
influenced by IL-6 kinetics [36]. Cryptococcus similarly promotes an imbalance toward a Th2 response
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by suppressing Th1 responses via IL-12 produced by macrophages [37–39]. Together, the influence
of IL-6 and cryptococcal infection could promote poor antigen clearance, persistence of residual
antigen, and subsequent risk of CM-IRIS, consistent with the elevated serum CrAg titer among those
pre-disposed to CM-IRIS.
We found elevated monocyte IL-6 expression among participants with CM-IRIS compared
to controls without IRIS. Barber and colleagues have demonstrated in a murine model of
experimentally-inducible Mycobacterium avium IRIS that by neutralizing IL-6, C-reactive protein
levels diminished, wasting disease was alleviated, and host survival was prolonged [40]. Further,
combined blockade of IL-6 and IFN-γ further reduced IRIS pathology even after onset of wasting
disease, pointing to the possible role of the IL-6 pathway in the immunopathology of IRIS. Our results
are consistent with a few other human studies that have demonstrated elevated IL-6 during CM-IRIS,
which show different cytokine responses in CSF and blood [9,13]. We posit that an anti-IL-6 monoclonal
antibody (e.g., siltuximab) could be further evaluated in understanding the efficacy of alleviating the
pathology and mortality associated with cryptococcal IRIS in the enclosed central nervous system
space cognizant of its pleotropic nature. Despite the increased risk of developing cryptococcosis among
patients using anti-TNF antagonists [41,42], a therapeutic option to evaluate in larger studies would be
to target inhibition of TNF-α for the alleviation of the neurological symptoms associated with CM-IRIS,
as suggested in two case reports [43,44]. However, the clinical response may be variable by person.
The frequency of activated monocytes co-expressing PD-L1 and CD25 was increased at CM-IRIS
compared with that in matched controls. PD-L1, expressed by various effector cytokines, has the ability
to co-stimulate naïve T cells and co-inhibit effector T cells through the programmed cell death protein 1
(PD-1) receptor, and is expressed on most activated immune cells [45,46]. IFN-γ induces monocytes to
express TNF-α and IL-6, both of which were elevated during CM-IRIS compared to CM diagnosis and
to controls without CM-IRIS in response to IFN-γ stimulation. Thus, increased monocyte activation
and restored cytokine responses to IFN-γ signaling from recovering CD4+ T cells appear to coincide
with the timing of CM-IRIS, consistent with the prior proposed paradigm [9,18].
Taken together, elevated frequencies of activated monocytes, our previously published data
showing the presence of proinflammatory intermediate monocytes in CSF [47], the elevation of IL-6
during CM-IRIS [9,13], and our data showing increased monocyte cytokines at baseline suggest
monocyte dysregulation associated with augmented disease. Moreover, data showing increased CCL2
and CCL3 chemokines in the CSF compared with blood [48], and the association between baseline
CCL2, CCL3, and GM-CSF expression in CSF and subsequent IRIS [49], suggest enhanced trafficking
of activated monocytes from blood into the CSF during CM-IRIS. In addition, within the overall COAT
trial, we found that earlier ART initiation was associated with CSF microglial/macrophage activation
and increased cellular infiltrate in persons with cryptococcal meningitis [50].
Higher fungal burden or cryptococcal antigen titer at CM diagnosis is known to be a risk factor
for poor outcomes and CM-IRIS [9–11]. Participants with CM-IRIS in our study had a tendency to
have higher cryptococcal quantitative colony counts compared to control participants at baseline.
Despite the small sample size, our findings provide a basis for further examining correlations
between monocyte subsets, antigen burden, cytokine responses, and clinical outcomes in larger studies.
We did not have a sufficient sample size to evaluate the correlation of our findings with ART timing,
as there were only six participants with IRIS in the deferred arm and four participants in the early
arm of the COAT trial [19]. We studied monocyte function in peripheral blood and not directly in the
CNS, the site of CM-IRIS pathology, thus limiting extrapolation to CSF. Although these data may not
mirror compartment-specific responses, they may be reflective of monocytes already exposed and
exhausted following IFN-γ signaling in vivo during CM-IRIS, thus we interpret the cytokine responses
with some caution. Due to the overlap and a degree of heterogeneity in IL-6 responses among those
who developed CM-IRIS and controls who did not develop CM-IRIS, we can only surmise that IL-6
could be a co-predictor of increased risk for CM- IRIS. Nevertheless, building on our previous studies
of CM-IRIS using cytokine levels in serum [9] and CSF [13], an instructive feature of this study is the
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detection of augmented monocyte cytokine responses at the single cell level prior to the development
of and during cryptococcal IRIS. There was likely a gender bias in the selection of controls, since we
did not match on gender, however, we do not envisage any correlation between gender and cytokine
expression during IRIS.
In conclusion, we have demonstrated that monocyte subset phenotype and cytokine responses
prior to ART are associated with and may be predictive of CM-IRIS. Larger studies to further delineate
innate immunological responses and the efficacy of immunomodulatory therapies during cryptococcal
IRIS are warranted.
Supplementary Materials: Supplementary materials can be found at: www.mdpi.com/2309-608X/3/2/28/s1.
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